GenVec, Inc.

( )
GNVC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc.
JNJJohnson & Johnson
MRKMerck & Co., Inc.
LLYEli Lilly and Company
ABBVAbbVie, Inc.
BMYBristol-Myers Squibb Company
NVSNovartis AG Sponsored ADR
AZNAstraZeneca PLC Sponsored ADR
GSKGlaxoSmithKline plc Sponsored ADR
NVONovo Nordisk A/S Sponsored ADR Class B
SNYSanofi Sponsored ADR
LCILannett Company, Inc.
AKTXAkari Therapeutics Plc Sponsored ADR

Company Profile

GenVec, Inc. is a clinical-stage gene delivery company, which engages in the development of therapeutics and vaccines. The firm designs, tests, and manufactures adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products include CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and is headquartered in Gaithersburg, MD.